Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Triple Negative Breast Cancer Clinical Trial

Official title:

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04452370
• Other study ID #: NCC2225
• Status: Recruiting
• Phase: Phase 2
• Start date: September 23, 2020
• Est. completion date: July 11, 2023

Study information

• Verified date: July 2021
• Source: Chinese Academy of Medical Sciences
• Contact: Peng Yuan
• Phone: 01087787245
• Email: yuanpeng01[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The hypothesis of this study is to discover if the oral Etoposide plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC. It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer

Description:

It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer. The hypothesis of this study is to discover if the oral Etoposide plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: July 11, 2023
• Est. primary completion date: July 11, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 75 year-old women; TNBC
• ECOG score: 0-1, expected survival time = 3months;
• Pathologically or cytologically confirmed breast cancer;
• Anthracycline- / taxane- pretreated (adjuvant, neoadjuvant) breast cancer patients who have failed from 1-3 standard chemotherapies after recurrence and metastasis;
• According to RECIST 1.1, exist at least =1 measurable lesion(CT >1cm,other examination >2cm);
• The patients have enough organ function. The laboratory test indexes must comply with

the following requirements:

• Blood routine: neutrophil=1.5G/L, platelet count =80G/L, hemoglobin =90g/L
• Liver function: serum bilirubin = 1.5 times the upper limit of normal value; ALT and AST=2.5 times the upper limit of normal value; ALT and AST=5 times the upper limit of normal value when liver metastasis
• Renal function: serum creatinine = 1.0times the upper limit of normal value, creatinine clearance >50ml/min(Cockcroft-Gault formula)
• Women of child-bearing age should be carried out pregnancy test (serum or urine) within 7 days before recruit, the results should be negative; and are willing to adopt the appropriate methods of contraception during the trial and 8 weeks after last administration;
• Can swallow oral drugs;
• The patients have good compliance to the therapy and follow-up to be scheduled and are able to understand the study protocol and sign the Informed Consent Form.

Exclusion Criteria:

• The patients in pregnancy or lactation growth period and did not take effective contraception;
• The patients who received =4 chemotherapies after recurrence and metastasis; involved in other clinical trials four weeks prior to the start of the study;
• The patients with a variety of factors that affect the oral administration and absorption of drugs;
• Prior treatment with etoposide or antiangiogenic TKI (subjects with prior use of antiangiogenic macromolecules such as bevacizumab are allowed to be enrolled);
• The patients have uncontrollable mental illness;
• Serous cavity effusion (such as pleural effusion and ascites) with clinical symptoms requiring clinical intervention or stable time less than 4 weeks;
• The patients who had serious adverse effect to oral etoposide or were allergic to etoposide.
• The patients who have only bone metastasis without other measurable lesion;
• The patients experience severe cardiovascular diseases;
• The patients experience severe upper gastrointestinal ulcer or malabsorption syndrome.
• Abnormal bone marrow functions(neutrophil<1.5G/L, platelet count <75G/L, hemoglobin <90g/L);
• Abnormal renal function(serum creatinine > 1.5 times the upper limit of normal value);
• Abnormal liver function(serum bilirubin = 1.5 times the upper limit of normal value);
• The patients have uncontrollable brain metastasis;
• Active or uncontrolled infection requiring systematic treatment (except simple urinary tract infection or upper respiratory tract infection) during the 2 weeks or 2 weeks prior to enrollment;
• Previous or concurrent history of other malignant tumors.Except for the cured skin basal cell carcinoma and cervical carcinoma in situ;
• The patients do have good compliance to the therapy.

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• oral etoposide + anlotinib
anlotinib 12mg qd, d1-14,21days/cycle oral etoposide 75mg qd,d1-10,21days/cycle

Locations

Country	Name	City	State
China	Cancer Institute & Hospital. Chinese Academy of Medical Sciences	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	objective response rate(ORR)	The ORR will be defined as the proportion of patients in the Efficacy Evaluable patient Set who achieve complete response (CR) and partial response (PR)	up to 1 year after the last patient enrolled
Secondary	Progression free survival(PFS)	PFS will be defined as the time from first dose of study drug until documentation of disease progression or death from any cause	up to 1 year after the last patient enrolled
Secondary	Incidence and Severity of adverse events	hematologic,hepatotoxicity,Incidence of hypertension,Incidence of proteinuria	approximately 1.5 years